MDxHealth SA and University of Oxford Collaborate on Study to Evaluate the Correlation Between Genomic Prostate Score and Prostate Cancer Progression

MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, has announced a research collaboration with the University of Oxford. This collaboration aims to explore the correlation between the Genomic Prostate Score (GPS) test and the progression of prostate cancer in individuals who have undergone treatment for localized prostate cancer.
Prostate cancer is a prevalent and potentially deadly condition that affects men worldwide. While treatments are available, the variability in patient outcomes highlights the need for enhanced risk assessment and personalized treatment approaches. The partnership between MDxHealth and the University of Oxford seeks to address this pressing issue. Ian Mills, PhD, John Black Professor of Prostate Cancer at the University of Oxford, expressed his enthusiasm for this collaboration: “Prostate cancer is a prevalent male cancer that can develop into metastases in certain cases, underscoring the urgent need for improved risk stratification through disease profiling and biological modeling. We are excited to collaborate with MDxHealth to validate the GPS test’s potential to enhance risk assessment in men diagnosed with localized prostate cancer.”
The Genomic Prostate Score (GPS) test, developed by MDxHealth is a genomic assay designed for men with localized prostate cancer, including low-, intermediate-, and high-risk cases. It analyzes prostate cancer gene expression activity to predict disease aggressiveness. The GPS test has been developed and studied in over 10,000 patients and the test’s 17-gene signature includes genes related to cancer and biological pathways. It predicts the likelihood of adverse pathology, prostate cancer death, and metastasis within 10 years. The GPS test is suitable for patients with localized prostate cancer, from clinically low-risk to high-risk cases and is used to inform clinical treatment decision making for physicians and patients. Every year in the United States approximately 280,000 men are diagnosed with prostate cancer.
As part of this research initiative, MDxHealth will perform GPS testing on patient samples sourced from the Prostate Mechanisms of Progression and Treatment (ProMPT) cohort. The ProMPT cohort, initiated in 2002, is a collaborative translational research effort involving multiple cancer research programs in the United Kingdom. It collects biological samples and clinical data from participants to advance our understanding of prostate cancer.